14 Jun 2021 14:08
14 June 2021
SourceBio International plc
('SourceBio')
RESULT OF ANNUAL GENERAL MEETING
SourceBio confirms that all resolutions put to the 2021 Annual General Meeting held on the 14 June wereduly passed by the required majority.
Voting on the resolutions was as follows:
Resolution | Description | For | Against | Withheld |
1 | To receive and approve the Company's Annual Report and Accounts for the financial year ended 31 December 2020 together with the Directors' Report (including the Strategic Report) and the Auditor's Report. | 58,529,422 | 802 | 400 |
2 | To receive and approve the Directors' Remuneration Report for the financial year ended 31 December 2020, excluding the proposed remuneration policy, executive share options plan and Save As You Earn ("SAYE") scheme. | 58,523,385 | 7,239 | Nil |
3 | To approve the proposed remuneration policy expected to be applied in 2021. | 57,772,392 | 8,232 | 750,000 |
4 | To approve the establishment and implementation of a proposed executive share options plan. | 57,767,232 | 8,392 | 755,000 |
5 | To approve the establishment and implementation of a proposed SAYE scheme. | 58,527,668 | 1,556 | 1,400 |
6 | To re-elect Jay LeCoque (Executive Chairman) as a Director of the Company. | 58,529,756 | 868 | Nil |
7 | To re-elect Tony Ratcliffe (Chief Financial Officer) as a Director of the Company. | 58,530,624 | Nil | Nil |
8 | To re-elect Sir Ian Carruthers (Senior Independent Non-Executive Director) as a Director of the Company. | 58,526,545 | 3,748 | 331 |
9 | To re-elect Simon Constantine (Independent Non-Executive Director) as a Director of the Company. | 58,529,091 | 1,533 | Nil |
10 | To re-elect Marco Fumagalli (Non-Executive Director) as a Director of the Company. | 58,529,956 | 668 | Nil |
11 | To re-elect Christopher Mills (Non-Executive Director) as a Director of the Company. | 58,528,891 | 1,733 | Nil |
12 | To re-appoint RSM UK Audit LLP as auditor of the Company and to authorise the Directors to fix their remuneration. | 58,529,024 | 1,600 | Nil |
13 | To authorise the Directors generally to allot ordinary shares up to the specified limit. | 58,524,551 | 5,673 | 400 |
14 * | To empower the Directors to issue shares free from statutory pre-emption rights up to the specified limit. | 58,518,215 | 12,409 | Nil |
15 * | To authorise amendment to the Company's Articles of Association. | 58,524,345 | 1,279 | 5,000 |
* Special Resolution
A trading update was released at 7.00am this morning.
Notes:
· Any proxy appointments which gave direction to the Executive Chairman have been included in the "for" column;
· The total number of shares in issue is 74,183,038
Contacts:
SourceBio International plc | www.sourcebiointernational.com | |
Jay LeCoque, Executive Chairman | Via Walbrook PR | |
Tony Ratcliffe, Chief Financial Officer |
| |
|
| |
Liberum (Nominated Advisor and Broker) | Tel: 020 3100 2000 | |
Bidhi Bhoma Richard Lindley |
| |
Euan Brown |
| |
|
| |
Walbrook PR Limited | Tel: 020 7933 8780 or sourcebio@walbrookpr.com | |
Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 | |
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:
· Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups, NHS and the DHSC. Utilising multiple technologies, SourceBio offers screening, gold standard RT-PCR and whole genome sequencing COVID-19 testing solutions and operates under ISO 15189 accreditation required by the DHSC. SourceBio also provides employee testing solutions to industry, direct to consumer home test kits (including 'Fit to Fly', 'Test to Release' and '2 & 8 Day International Travel' approved tests) whilst also being the lead operator on mobile testing unit services to support outbreak testing for the DHSC, event and venue testing.
· Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.
· Genomics - DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.
· Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here: www.sourcebioscience.com
SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.